Just a few years in the past, I interviewed a Black teen as a part of a examine on the well being of Gen Z. What this ninth-grader from an inner-city group was most obsessed with shocked me.
“In eighth grade, lunch was one thing tasty; I might eat it,” she advised me. “Right here we go now: 65% diminished fats. Barely any seasoning. I’m like, ‘What is that this crap?’”
She was speaking concerning the healthy meals program being rolled out in California K-12 schools like hers as a part of the Obama administration’s effort to tame the nation’s childhood weight problems epidemic.
I urged to her that the federal government’s lunch initiative — which to be honest was additionally deeply disliked by a lot of adults, namely Republicans in Congress — may assist teenagers she knew drop a few pounds or stave off diabetes. She wasn’t having it. “Once they get dwelling,” she mentioned of her friends, “they’re going to eat a thousand baggage of sizzling Cheetos.”
Roughly 30% of Los Angeles Unified College District college students are overweight or obese, uncannily mirroring the speed amongst Los Angeles County adults. Black and Latino people are disproportionately represented in every group, making town floor zero for this persistent, racialized epidemic. And by 2030, a staggering 41.5% of California adults, a superb portion of whom can be Black and Latino members of Gen Z, are anticipated to be overweight.
In America, weight problems charges are consistently higher among racial minorities relative to white populations. The identical sample exists for kind 2 diabetes, with nonwhite people having a higher burden of the complex disease. Disproportionately lower levels of access to healthy, affordable foods and limited access to infrastructure and amenities that promote physical activity function the first culprits. The downstream results, a lower quality of life and a higher likelihood of premature death, are grave.
GLP-1s, the seemingly magic medication able to dramatically decreasing diabetes and obesity-related points, appear to be an apparent — or at the very least probably the most environment friendly — resolution to this preventable public well being disaster. However research persistently present that, regardless of their elevated want, racial minorities receive significantly fewer prescriptions for GLP-1s. And it’s not essentially from an absence of making an attempt on the a part of Large Pharma, an business wanting to broaden its buyer base. In truth, in the previous couple of years, Large Pharma and its allies have labored laborious to carry minority prospects into the GLP-1 fold.
In 2021, Novo Nordisk, the maker of Ozempic and Wegovy, sponsored a panel on obesity at a convention held by the highly effective Congressional Black Caucus. Final yr, the mammoth pharmaceutical firm organized an analogous panel for the influential National Assn. of Hispanic Nurses.
Oprah Winfrey, whose battles with weight reduction are well-documented, hosted a highly publicized ABC special on GLP-1s in 2024. The billionaire media persona previously served as a board member and spokesperson for Weight Watchers, which now provides a subscription-based program offering prospects with entry to numerous GLP-1s. Winfrey later discussed in an interview the profound methods the medication helped her quiet the “meals noise” round her. And in 2025, telehealth firm Ro, which has its personal GLP-1 distribution service, unveiled a partnership with tennis megastar Serena Williams, who used GLP-1s to handle her postpartum weight achieve.
A bunch of well-known Black and Latino social media influencers have additionally served as boosters for GLP-1s (and, by extension, Large Pharma’s outreach efforts).
The decrease adoption of GLP-1s by racial minorities has been, satirically, largely of Large Pharma’s making. Racial minorities continuously aren’t included within the formative scientific trial testing section by which medication are optimized to potential sufferers’ organic and cultural nuances. The dearth of participation is each a operate of researchers’ traditionally gentle curiosity in together with minorities in research and minorities’ personal mistrust and fears about collaborating.
Regardless of consciousness of those participation gaps, which return a long time, there have been only marginal improvements in minorities’ representation in scientific research, together with these for GLP-1s. A review of scientific trials performed with GLP-1s discovered that Black and Latino individuals have been considerably underrepresented relative to white individuals.
There’s additionally the stingy concern of worth. Totaling a mean of nearly $7,000 annually, the prices of GLP-1s are merely untenable for the numerous racial minorities who lack the earnings or premium insurance coverage wanted to cowl the bills. Certainly, a lot of personal and public insurers are nonetheless solely marginally covering the costs of GLP-1s, if in any respect.
Medicaid protection for GLP-1s is presently non-compulsory for states. Solely 13 currently cover GLP-1s for weight problems remedy , and that largely doesn’t embrace states with massive racial minority populations coping with weight problems like Florida and Texas. Regardless of outcry, Medi-Cal severed coverage of GLP-1s for weight reduction earlier this yr as a part of a broader budget-trimming effort in California. GLP-1 protection via Medicare, which traditionally has been hostile to covering weight loss drugs, is much more restricted. Nevertheless, the Facilities for Medicare & Medicaid Companies, which administers Medicare, started a pilot program in July to offer protection to some Medicare beneficiaries. This program could present a path for reducing GLP-1s’ steep monetary burden for low-income minorities, however even when it’s profitable, different obstacles exist to racially equitable uptake.
For one, regardless of their mainstreaming, GLP-1s nonetheless haven’t totally shed their picture as an amenity for white elites and at odds with the body positivity movement. Years of social conditioning across the white female beauty standard — one exalting thinness — could push some racial minorities to outright reject GLP-1s and the bodily gentrification the medication appear to facilitate. Relatedly, some imagine GLP-1s are a shameful shortcut, misaligned with the grit we historically affiliate with “actual” health. By the way, although, a 2024 Pew poll discovered that 70% of Black individuals and 68% of white individuals really feel that willpower alone is often not sufficient to drop a few pounds and hold it off.
I requested that Black teen a number of years in the past what a possible reply to the weight problems epidemic could possibly be, and he or she was clear: “Should you’re going to have any individual eat wholesome, pair it with exercising. Or it ain’t doing nothing.”
GLP-1s’ success largely upends such typical knowledge. That these medication could be an all-in-one resolution is turning into more and more apparent, even to naysayers. Whether or not we must always enable them to be is a really completely different — and really racialized — query.
Jerel Ezell is a sociologist and assistant professor on the College of Chicago Medical Middle.
